Type 2 & other diabetes

A Systematic Review and Meta-analysis on the Safety and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitor Use in Hospitalized Patients

Diabetes CarePublished Systematic review and meta-analysis of randomized controlled trials (RCTs) and observational cohort studies

Pooled result · KetoacidosisResult — go to the resultRate ratio 1.50 95 CI 0.56–4.23

Authors' conclusion

SGLT2 inhibitor use among hospitalized patients was associated with numerically higher rates of ketoacidosis, although further studies are required.

Study context

Population
Patients hospitalized for any reason; RCTs: 29.5% with T2D
Participants
19,846 patients23 RCTs
Comparison
SGLT2i vs placebo or active comparator
Outcome
Ketoacidosis
Methodological detailsrandom-effects meta-analysis, RCTs and cohort studies analysed separately, Ketoacidosis rates were low, likely limiting power to detect differences
  • Random-effects meta-analysis
  • RCTs and cohort studies analysed separately
  • Ketoacidosis rates were low, likely limiting power to detect differences

Pooled result

As reported in the abstract

Rate ratio

1.50

95 CI 0.56–4.23

P = 0.38

By group

SGLT2i

0.210 per 100 person-years

CI 0.119–0.370

Control

0.140 per 100 person-years

CI 0.070–0.280

SGLT2ivs Control
rate ratio 1.50 (95 CI 0.56–4.23); P = 0.38

Further pooled results

OutcomeORP value
Readmissions and urgent visits, HF trialsSGLT2ivs ControlFewer with SGLT2i0.64 (95 CI 0.47–0.86)P < 0.01
Mortality, HF trialsSGLT2ivs Control0.74 (95% CI 0.56–0.98)P = 0.03

Safety

OutcomeOR (95% CI)P value
Acute kidney injury, all RCTsSGLT2ivs ControlLower incidence with SGLT2i0.76 (0.60–0.97)P = 0.03

Adverse events, observational studies

20 observational studies did not show increased adverse events

Original publication

A Systematic Review and Meta-analysis on the Safety and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitor Use in Hospitalized Patients. Diabetes Care. Published 27 November 2024. doi:10.2337/dc24-0946

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.